Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial

Before February, 2021, there was no standard treatment regimen for locally advanced basal cell carcinoma after first-line hedgehog inhibitor (HHI) therapy. Cemiplimab, a PD-1 antibody, is approved for treatment of advanced cutaneous squamous cell carcinoma and has shown clinical activity as monother...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The lancet oncology Ročník 22; číslo 6; s. 848 - 857
Hlavní autori:	Stratigos, Alexander J, Sekulic, Aleksandar, Peris, Ketty, Bechter, Oliver, Prey, Sorilla, Kaatz, Martin, Lewis, Karl D, Basset-Seguin, Nicole, Chang, Anne Lynn S, Dalle, Stèphane, Orland, Almudena Fernandez, Licitra, Lisa, Robert, Caroline, Ulrich, Claas, Hauschild, Axel, Migden, Michael R, Dummer, Reinhard, Li, Siyu, Yoo, Suk-Young, Mohan, Kosalai, Coates, Ebony, Jankovic, Vladimir, Fiaschi, Nathalie, Okoye, Emmanuel, Bassukas, Ioannis D, Loquai, Carmen, De Giorgi, Vincenzo, Eroglu, Zeynep, Gutzmer, Ralf, Ulrich, Jens, Puig, Susana, Seebach, Frank, Thurston, Gavin, Weinreich, David M, Yancopoulos, George D, Lowy, Israel, Bowler, Timothy, Fury, Matthew G
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Elsevier Ltd 01.06.2021 Elsevier Limited Elsevier
Predmet:	Adverse events Basal cell carcinoma Cancer Colitis FDA approval Hematology, Oncology, and Palliative Medicine Immunotherapy Intolerance Life Sciences Lung cancer Metastases Metastasis Monoclonal antibodies Non-small cell lung carcinoma Patients PD-1 protein Photography Radiation therapy Radiology Skin cancer Squamous cell carcinoma Statistical analysis Surgery Targeted cancer therapy Toxicity Tumors United States > US
ISSN:	1470-2045, 1474-5488, 1474-5488
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!